Research programme: HIV fusion inhibitors - Borean Pharma
Latest Information Update: 04 Nov 2017
At a glance
- Originator Borean Pharma
- Class
- Mechanism of Action HIV fusion inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported HIV infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in HIV-infections in Denmark
- 23 Oct 2007 This programme is still in active development
- 25 Feb 2004 Preclinical trials in HIV infections treatment in Denmark (unspecified route)